Intellia Therapeutics, Inc. (NTLA)
- Sector
- Biotechnology
- Last price
- $13.32
- As of
Kresmion compiles this page from NTLA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Intellia Therapeutics, Inc. (NTLA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full NTLA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NTLA on one page. Preview it with sample data, then open it live with a free account.
Preview the NTLA dossierActive events for NTLA
- high13F: large reduction
CITADEL ADVISORS LLC cut 50% of NTLA (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of NTLA (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 67% of NTLA (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +432% to NTLA (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +1376% to NTLA (2026Q2)
FREE, NO ACCOUNT
Every event on NTLA, as it fires
You are seeing 5 of 12 events recorded on NTLA since 2026-06-04.
The five above all landed on 2026-08-16. The other 7 were recorded on 2 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NTLA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 45826J105 · 2026Q2 | $109M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45826J105 · 2026Q2 | $88.6M | 0.06% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45826J105 · 2026Q2 | $23.7M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45826J105 · 2026Q2 | $8.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 45826J105 · 2026Q2 | $6.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 45826J105 · 2026Q2 | $2.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NTLA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NTLA against its peers
NTLA's operating margin of -651.7% ranks in the 28th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | NTLA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 67.7M USD | 110M USD | 34 | 15 |
| Gross margin | n/a | 89.5% | n/a | 7 |
| Operating margin | -651.7% | -85.3% | 28 | 15 |
| Net margin | -609.9% | -81.9% | 26 | 16 |
| Return on equity | -61.5% | -33.6% | 23 | 14 |
Peers (19): ZBIO, MLYS, MAZE, MESO, QURE, NBTX, VIR, ABSI, SRPT, SLS, STOK, NVAX, CMPS, RARE, SEPN, ZYME, IMCR, VCEL, URGN. Left out: TRAX (no annual filing), COAG (no annual filing), BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing), KLRA (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NTLA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NTLA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NTLA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.